Clinical trials
Advanced Solid Cancer clinical trials
Below are recruiting advanced solid cancer clinical trials, each written for real people, not researchers. We’re tracking 1,320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05705492RecruitingPhase 2
Olanzapine to help cancer-related weight and appetite loss
This Phase 2 trial tests whether olanzapine can help people with advanced cancer who are losing weight and not eating enough. It looks for improvements in appetite and weight while you receive your first-line palliative cancer treatment.
Portland, OregonAges 18 years+ - NCT05053971RecruitingPhase 1/Phase 2
Entinostat plus ZEN003694 for advanced solid tumors
This Phase 1/2 study tests a new combination anti-cancer treatment (entinostat plus ZEN003694) in people with advanced solid tumors that can’t be controlled with standard care. It aims to find a safe dose and see whether the treatment can shrink tumors or control the disease.
New Haven, ConnecticutAges 18 years+ - NCT03175224RecruitingPhase 2
Test drug APL-101 for lung or other tumors with MET changes
This Phase 2 study tests APL-101 to shrink advanced cancers that have certain MET-related changes, including specific MET mutations, MET gene amplification, or MET fusions. It may help people whose tumors have run out of standard treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Birmingham, AlabamaAges Any age - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT03829254RecruitingPhase 1/Phase 2
NUC-7738 treatment for advanced solid cancers and lymphoma
This early-phase study tests how safe NUC-7738 is and how it works in people with advanced solid tumors and certain lymphomas. Some participants may also receive pembrolizumab for specific cancers, aiming to improve cancer control while carefully monitoring side effects.
CambridgeAges 18 years+ - NCT03917043RecruitingPhase 1
Testing a new targeted drug for ALK or ROS1 lung cancers
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03943004RecruitingPhase 1
Study drug DFP-14927 for advanced solid tumors
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
Los Angeles, CaliforniaAges 18 years+ - NCT07583654RecruitingPhase 1
Testing a New mRNA Cancer Treatment for Advanced Solid Tumors
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
Chengdu, SichuanAges 18–70 - NCT07702162RecruitingPhase 1
Testing PA5 in advanced solid tumors
This trial tests a new drug called PA5 for people with advanced solid tumors that no longer respond to standard treatments. The goal is to see if PA5 is safe and how well it works against these cancers.
Fuzhou, FujianAges 18 years+ - NCT04015609Recruiting
Spanish therapy sessions for Latino people with advanced cancer
This study tests a psychotherapy (talking/support) intervention designed for Latino/Hispanic adults with stage III or IV solid tumor cancer. It uses Spanish-only questionnaires and interviews, and may help by addressing emotional distress during advanced cancer care.
New York, New YorkAges 18 years+ - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04421820RecruitingPhase 1/Phase 2
BOLD-100 with chemo for advanced gut cancer
This Phase 1/2 study tests whether BOLD-100, given with the standard chemo combination FOLFOX, can help people with advanced gastrointestinal cancers. It’s especially focused on specific tumor features (including BRAF status) and checks safety, dosing, and early signs of effectiveness.
Santa Monica, CaliforniaAges 18 years+ - NCT04443088RecruitingPhase 1
Study drug INV-1120 with or without pembrolizumab for advanced cancers
This Phase 1 trial studies INV-1120 alone and with pembrolizumab (an immune therapy) in adults with advanced solid tumors that have stopped responding to standard treatment or have no standard option. The goal is to see how the treatments work, what dose is safest, and what side effects may occur.
Lafayette, IndianaAges 18 years+ - NCT04495790Recruiting
Cancer patient study to track health outcomes
This is an observational study that follows people with cancer to better understand outcomes over time. You may be asked to complete questionnaires and share information from your visits (in person or by video only if you meet their rules).
Seattle, WashingtonAges Any age - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04827810RecruitingPhase 1
IV gamitrinib study for advanced cancers needing new options
This early-phase trial tests how safe IV gamitrinib is and how the body processes it in people with advanced cancers that can’t be controlled by standard treatment. It may also help researchers learn the best dose and whether it has signs of anti-cancer activity.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid cancer?
- Yes. Clin2 currently lists 1,320 recruiting advanced solid cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.